Latest News

Six Australian health and medical technology startups have secured a combined $13.5 million through the second funding round of CUREator+, as the national commercialisation program seeks to move locally developed therapies, diagnostics and digital health tools closer to patients and private investment.

QIMR Berghofer researchers have created a detailed new map of the chemical signals that influence heart function, in a development that could help accelerate the discovery of new treatments for heart disease.

CLINUVEL has identified a lead formulation from its VLRX L controlled-release injectable peptide platform and plans to progress it into further preclinical studies in the first quarter of 2027.

Perth biotechnology company Spartan Therapeutics says it plans to begin a human clinical trial in 2027 of a circular RNA platform designed to restore more youthful function in organs and tissues across the body.

Starpharma has completed its fully underwritten $32 million entitlement offer, securing strong backing from existing shareholders as it prepares to advance its DEP HER2-Lutetium oncology program into first-in-human clinical testing.

AusBiotech has unveiled the integrated program for the 2026 AusBiotech International Conference and AusMedtech Conference, bringing more than 250 speakers together across approximately 60 sessions on the Gold Coast in October.

Percheron Therapeutics, previously known as Antisense, has appointed biotech executive Dr Michael Baker as its new chief executive officer and managing director, as current CEO Dr James Garner prepares to leave the role for an overseas opportunity.

AdAlta has reported continued survival among patients in its early-stage Chinese study of EW-001, with all five participants remaining alive at the company’s March update and still in follow-up as of July.

A patient treated with a single dose of AdAlta’s experimental CAR T cell therapy EW 001 has remained free of cancer recurrence for two years, marking a significant milestone in the company’s ongoing mesothelioma study in China.

Clarity Pharmaceuticals has reported two additional complete responses among participants receiving its investigational radiopharmaceutical 67Cu-SAR-bisPSMA in the SECuRE trial, bringing the total number of complete responses or cases of undetectable disease across the company’s program to seven.

QIMR Berghofer and James Cook University have strengthened their strategic partnership to establish one of Australia’s leading collaborations in tropical health research, with a focus on accelerating the development of vaccines, diagnostics and therapeutics while preparing the next generation of health researchers.

Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner, Acadia Pharmaceuticals, reporting net sales of US$125 million in the second quarter of 2026.